Evaluating the effects of tasurgratinib in patients with mild to moderate liver impairment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess how mild and moderate hepatic impairment affects the pharmacokinetics of tasurgratinib after a single dose administration. Participants with stable hepatic impairment will be compared to healthy individuals matched by age, weight, race, and gender. The study will involve administering tasurgratinib and monitoring its absorption, distribution, metabolism, and excretion in the body. The findings could provide insights into the drug's safety and efficacy in patients with liver conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Body mass index (BMI) between 18 to 40 kilogram per square meter (kg/m\^2).
2. For Cohorts A and B: stable hepatic impairment conforming to Child-Pugh classification A and B.
3. For Cohort C: healthy participants matched to participants with hepatic impairment with regard to age (+/-10 years), body weight (+/-20 percent \[%\]), race and gender, and as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram (ECG), and clinical laboratory determinations.

Exclusion Criteria:

Key Exclusion for all Participants:

1. Following ocular disorders

   1. Current evidence of Grade 2 or higher corneal disorder
   2. Current evidence of active macular disorder (example, Age-related macular degeneration, central serous chorioretinal disease)
2. Known to be human immunodeficiency virus (HIV) positive at Screening.
3. A prolonged QT/QTc interval (\[QT interval using Fridericia's formula\] QTcF greater than (\>) 480 millisecond \[ms\]) demonstrated on ECG.

Additional Exclusion Criteria for Hepatically Impaired Participants (Cohorts A and B)

In addition to the Exclusion Criteria above for all participants, other standard exclusion criteria for participants with hepatic impairment will be used. These include:

1. Any significant acute medical illness (such as new conditions or exacerbation of pre-existing conditions) within 8 weeks of dosing.
2. Presence of severe ascites, edema, or uncontrolled hepatic encephalopathy
3. The participant's standard therapy/concomitant medication for diseases related to hepatic disease has not remained stable/unchanged for at least two weeks before dosing of study drug.

Additional Exclusion Criteria for Healthy participants (Cohort C)

In addition to the Exclusion Criteria for all participants, other standard exclusion criteria for healthy participants in Phase 1 studies will be used. These include:

1. Syphilis as demonstrated by positive serology at Screening.
2. Any abnormal finding based on physical examination, assessment of vital signs, ECG, or laboratory test results that requires treatment or clinical follow up based on investigators opinion.

Where it's running

• Eisai Trial Site #6
  Hakata, Fukuoka, Japan Recruiting
• Eisai Trial Site #2
  Yuhu, Oita Prefecture, Japan Recruiting
• Eisai Trial Site #3
  Bukyo-ku, Tokyo, Japan Recruiting
• Eisai Trial Site #1
  Mintato-ku, Tokyo, Japan Recruiting
• Eisai Trial Site #8
  Shinjuku-ku, Tokyo, Japan Recruiting
• Eisai Trial Site #5
  Kofu, Yamanashi, Japan Recruiting

Study contacts

• Study coordinator: Inquiry Service.
• Email: eisai-chiken_hotline@hhc.eisai.co.jp

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Casdatifan pharmacokinetics in moderate hepatic impairment vs normal liver function

  This study tests how a single dose of casdatifan behaves in people with moderate liver impairment compared to healthy individuals with normal liver function.

  Recruiting Phase 1 Arcus Biosciences, Inc. · San Antonio, Texas · NCT07751250

• How the medicine Atirmociclib behaves in people with healthy liver or with liver disease

  This study tests how atirmociclib is processed in the body and how safe it is for adults with normal liver function or with stable mild to severe liver disease.

  Recruiting at 3 sites Phase 1 Pfizer · Miami Lakes, Florida and 2 other locations · NCT07677358

• Treprostinil Palmitil Inhalation Powder: how liver function affects drug in a single-dose test

  This study tests how mild to severe liver impairment changes the amount of treprostinil palmitil and treprostinil in the body after one 80 mcg dose of TPIP in people with and without liver problems.

  Recruiting at 4 sites Phase 1 Insmed Incorporated · Lake Forest, California and 3 other locations · NCT07643155

• How liver impairment affects AZD9550 and AZD6234

  This trial will test how single subcutaneous doses of two investigational drugs, AZD9550 and AZD6234, are processed and tolerated in adults with moderate or severe liver impairment compared with matched healthy volunteers.

  Recruiting at 3 sites Phase 1 AstraZeneca · Chandler, Arizona and 3 other locations · NCT07546760

• How BI 3000202 behaves in the blood in people with and without liver problems

  This study tests how BI 3000202 moves through the body in healthy adults and adults with liver impairment.

  Recruiting Phase 1 Boehringer Ingelheim · San Antonio, Texas · NCT07486102

• Radiprodil for adults with liver impairment

  It will test whether a single 15 mg oral dose of radiprodil is processed differently and tolerated safely in adults with mild, moderate, or severe liver impairment compared with healthy adults.

  Recruiting at 2 sites Phase 1 GRIN Therapeutics, Inc. · DeSoto, Texas and 1 other locations · NCT07457229

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.